Business Wire

Capcom's Resident Evil Village Sales Top 10 Million Units Globally!

Share

Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Village surpassed 10 million*1 units in the three years since its 2021 release, making it the fastest title in the series to hit this milestone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611058824/en/

Worldwide sales of Resident Evil Village surpassed 10 million units (Graphic: Business Wire)

Resident Evil Village is the sequel to the lauded Resident Evil 7 biohazard, which was launched in 2017, and features a variety of horror experiences, a greater degree of action, and even more expansive, highly-engaging gameplay.

Following its 2021 release, the title garnered critical acclaim across the world after taking honors at the Golden Joystick Awards 2021 and Japan Game Awards: 2022 for its high degree of polish and emotionally resonant story that won over a broad range of game players worldwide. In addition, both the release of Resident Evil Village Gold Edition,which includes the main game and additional story content, and expanded support for devices such as iPhone 15 Pro have led to increased unit sales. Even now, three years after its release, the title continues to gain new users, selling approximately 2 million units each year. This has resulted in it achieving more than 10 million units in sales, making it the fastest title in the series to reach this milestone.

Capcom is firmly committed to satisfying the expectations of all users by leveraging its industry-leading game development capabilities in order to create highly entertaining gameplay experiences.

About the Resident Evil series:

The Resident Evil franchise features survival horror games in which players utilize a variety of weapons and other items to escape terrifying situations. Supported by a passionate global fanbase, cumulative game sales since the first title in this flagship series debuted in 1996 exceed 157 million*2 units. Further, the series features three titles with sales that exceed 10 million units: Resident Evil 7 biohazard, Resident Evil 2, and Resident Evil Village.

*1 Includes digital download sales
*2 As of March 31, 2024

ABOUT CAPCOM

Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611058824/en/

Contacts

Capcom Public Relations & Investor Relations Section
Daniel Levine
+81-6-6920-3623
daniel-levine@capcom.com

Yoshiko Ikeda
+81-6-6920-3623
yoshiko-ikeda@capcom.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: AIRA Challenge 2024 Prize awarded to Roboverse Reply for Mobile Robot Control via VR Glasses24.6.2024 11:00:00 EEST | Press release

Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. The competition invited world-leading experts to develop innovative solutions for enabling the remote control of mobile robots during autonomous inspections in production environments. Roboverse Reply’s platform demonstrates how Artificial Intelligence and human expertise can be combined to tackle challenging industrial tasks in real-world applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624606163/en/ Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. (Graphic: Business Wire) The final of the AIRA Challenge took place for the second time at ACHEMA, the world's largest trade fair fo

Takeda Announces Approval of LIVTENCITY ® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies24.6.2024 10:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval of LIVTENCITY in Japan, which will provide the transplant community with a new option for treatment of post-transplant CMV infection in patients refractory to other therapies,” said Yasushi Kajii, Head, R&D Japan Region at Takeda. “A diagnosis of CMV infection can be particularly challenging for patients, and serious complications such as increased organ rejection and hospitalization rates can occur, when not successfully treated. We believe LIVTENCITY has the potential to help address the challenges faced by people with post-transplant CMV and

Megaport and Lufthansa Systems Announce Landmark Partnership to Accelerate Airline Digital Transformation24.6.2024 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, and Lufthansa Systems, a leading aviation IT provider, today announced a new partnership that will accelerate digital transformation in the aviation industry. The strategic partnership will see Lufthansa Systems leverage Megaport’s global Software Defined Network (SDN) to securely and reliably move the global aviation cloud from a single cloud to multiple clouds by moving core routing from cloud to Megaport. Megaport will also facilitate a secure aviation customer landing zone to expedite peering with other airlines and exchanging data. Lufthansa Systems provides IT services to over 350 airlines worldwide. Its Global Aviation Cloud initiative aims to virtualise mission-critical airline applications and transition them to the cloud. Using Megaport’s private connectivity from resilient data centres, virtual firewalls, and virtual routing, Lufthansa Systems can securely and reliably connect

Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)24.6.2024 09:00:00 EEST | Press release

Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/ Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available. Seroba joined the consortium of investors leading the planned second closing of the Series B financi

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye